Published on: 04 November 2025

Unlocking Real-World Medication Patterns in Type 2 Diabetes Management

In managing type 2 diabetes, sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have become pillars of contemporary therapy. Despite their proven efficacy in clinical trials, real-world adherence and persistence remain significant challenges. This study offers a novel, integrated approach to understanding drug usage patterns over one year within a universal healthcare system, free from cost barriers. It sheds light on the nuanced behaviors surrounding adherence, discontinuation, and intolerance, crucial for optimizing therapeutic outcomes in clinical practice.

Novel Categorization of Drug Usage: Beyond Traditional Metrics

Unlike conventional studies that separate adherence and discontinuation analyses, this research combines these factors into five mutually exclusive categories: adherent, poor adherence, standard discontinuation, upper-bound discontinuation, and presumed intolerance (characterized by only a single dispensed prescription). This integrated method captures the full spectrum of medication use patterns, enabling more precise identification of clinical characteristics linked to each behavior. Such granularity allows healthcare professionals to tailor interventions more effectively.

Distinct Clinical Profiles Drive Adherence and Intolerance in SGLT2i Therapy

In the SGLT2i cohort, poor adherence predominantly affected younger patients experiencing greater socioeconomic deprivation and elevated baseline HbA1c levels. Conversely, intolerance—likely associated with adverse effects such as genitourinary infections—was more common among older, leaner females with a history of antifungal medication use. Interestingly, empagliflozin users showed a higher propensity for both poor adherence and intolerance compared to dapagliflozin, although this may partly reflect prescribing trends over time rather than intrinsic drug differences. Recognizing these distinct profiles enables clinicians to anticipate challenges and implement targeted support, particularly for vulnerable subgroups.

GLP-1RA Subclass Variability Influences Medication Persistence and Tolerability

GLP-1RA subclasses revealed greater variability in usage patterns. Newer agents, such as injectable semaglutide and dulaglutide, demonstrated superior adherence rates compared to older medications like liraglutide, lixisenatide, and exenatide. Notably, lixisenatide exhibited higher intolerance rates, often linked to gastrointestinal side effects. Poor adherence correlated with younger age and prior GLP-1RA exposure, whereas intolerance aligned with female sex, lower BMI, and advanced chronic kidney disease. These findings emphasize the importance of considering drug subclass characteristics when selecting therapy, especially for patients with complex clinical profiles.

The Impact of Adherence Patterns on Clinical Outcomes: A Closer Look

Sensitivity analyses within the empagliflozin subgroup revealed that poor adherence significantly compromises glycemic control and weight management benefits. Patients with suboptimal adherence achieved smaller reductions in HbA1c and BMI compared to adherent individuals. Moreover, discontinuation due to intolerance or other reasons corresponded with the poorest clinical outcomes. These insights underscore the critical need for monitoring adherence closely and addressing barriers promptly to maximize the therapeutic potential of SGLT2is and GLP-1RAs.

Socioeconomic and Behavioral Factors: Key Drivers of Medication Non-Persistence

The study highlights that social deprivation remains a formidable barrier to adherence, even in a healthcare system providing free prescriptions. This suggests that financial constraints are not the sole obstacle; instead, psychosocial and behavioral factors likely contribute significantly. Younger patients, in particular, demonstrated higher rates of poor adherence across both drug classes. Healthcare professionals must recognize these patterns and develop multifaceted strategies, including patient education, behavioral support, and regular follow-up, to improve persistence.

Clinical Implications for Healthcare Professionals in Muslim Weight Management

For healthcare providers managing type 2 diabetes within Muslim populations or similar contexts, understanding the interplay of clinical, demographic, and behavioral factors is vital. Tailoring medication choice and adherence support according to patient age, sex, BMI, kidney function, and social circumstances can enhance treatment sustainability. Additionally, distinguishing between poor adherence and intolerance allows for more precise interventions—whether through addressing side effects or behavioral barriers.

Strengthening Medication Management Through Integrated Data and Novel Approaches

This comprehensive, population-based study leverages rich longitudinal data, including clinical measurements and prescription dispensation records, to provide a realistic view of drug usage patterns. Incorporating hospitalization periods into adherence calculations further refines accuracy. The novel classification framework advances beyond traditional methods, offering healthcare professionals a robust tool to identify at-risk patients and optimize therapeutic regimens.

Conclusion: Advancing Type 2 Diabetes Care with Targeted Strategies

In conclusion, poor adherence and discontinuation of SGLT2is and GLP-1RAs stem from distinct clinical and psychosocial factors. Recognizing these differences is paramount for healthcare professionals aiming to improve long-term treatment outcomes. By applying these insights, practitioners can develop targeted, patient-centered strategies that promote sustained medication use, enhanced glycemic control, and better weight management—ultimately advancing care for individuals with type 2 diabetes.

SOURCE/READ FULL PAPER HERE: https://doi.org/10.1111/dom.70269

LEARN MORE ABOUT THE MUSLIM WEIGHT MANAGEMENT